SIRION Biotech presents at SACHS Forum in Zurich

Investment opportunities with viral vector technologies

(PresseBox) - SACHS Associates is holding its 7th Annual European Life Science CEO Forum for Partnering & Investing at the Zurich airport. SIRION Biotech is to present investment opportunities with viral vectors for gene studies, gene therapy and vaccines.

SIRION Biotech started in Munich in 2007 with the idea of enabling novel cell models closer to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 300 single projects with more than 100 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies.
www.SIRION-Biotech.com

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: PresseBox
Datum: 04.03.2014 - 15:19 Uhr
Sprache: Deutsch
News-ID 328083
Anzahl Zeichen: 1036

contact information:
Town:

Martinsried

Kategorie:

Handcrafts

Diese Pressemitteilung wurde bisher 368 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"SIRION Biotech presents at SACHS Forum in Zurich"
steht unter der journalistisch-redaktionellen Verantwortung von

SIRION BIOTECH GmbH (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

SIRION Biotech Granted CIR accreditation by French Ministry of Higher Education, ...

The French Ministry of Higher Education, Research and Innovation have granted SIRION Biotech a 3-year CIR (Crédit Impôt Recherche) accreditation lasting until end of 2023. As a result, SIRION Biotech GmbH is now on a list of experts accessible on t ...

Next-generation AAV gene therapy from joined German forces ...

The viral vector specialist SIRION Biotech GmbH today announces the signing of a preferred partnership agreement with Heidelberg University Hospital and AAV pioneer Prof. Dirk Grimm. This strategic alliance will enable both partners to offer engineer ...

SIRION Biotech and Vibalogics partner to offer complete Adeno-Associated Virus ( ...

SIRION Biotech GmbH and Vibalogics GmbH, have signed a strategic partnership agreement designed to meet demand from gene therapy companies for a start-to-finish Adeno-Associated Virus (AAV) service. The new service offering, which will be available f ...

Alle Meldungen von SIRION BIOTECH GmbH